Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 20/20 | 1.00 |
| ▸ | MMP1 | P03956 | 14/20 | 0.73 |
| ▸ | MMP2 | P08253 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443538 | 1.00 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6956789 | 0.85 | MMP3 (0.75) | MMP3MMP1MMP2 | |
| SCHEMBL6951416 | 0.85 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6952470 | 0.84 | MMP3 (0.72) | MMP3MMP1MMP2 | |
| SCHEMBL6954437 | 0.83 | MMP3 (0.81) | MMP3MMP1MMP2 | |
| SCHEMBL6954614 | 0.83 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL7341330 | 0.82 | MMP3 (0.80) | MMP3MMP1MMP2 | |
| SCHEMBL6953380 | 0.81 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6954588 | 0.81 | MMP3 (1.00) | MMP3MMP1MMP2 | |
| SCHEMBL6956280 | 0.81 | MMP3 (0.78) | MMP3MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745567-B2 | Compositions and methods for treating multiple sclerosis | REVALESIO CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9523090-B2 | Compositions and methods for treating inflammation | REVALESIO CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-9523090-B2 | Compositions and methods for treating inflammation | REVALESIO CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | REVALESIO CORPORATION (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100028443-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION | REVALESIO CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028443-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION | REVALESIO CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100028441-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | REVALESIO CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015235-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GJB2, GPR180 | MMP3 3758/4885MMP1 1996/4885MMP2 3607/4885 |
| US-20120114702-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | CHRM3, CHRNG, GRK3 | MMP3 3032/4885MMP1 1698/4885MMP2 2528/4885 |
| US-20100028443-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION | EPCAM, GPR180, GJA1 | MMP3 2700/4885MMP1 1268/4885MMP2 2975/4885 |
| US-20100004189-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | CFTR, GJB2, KRAS | MMP3 3582/4885MMP1 748/4885MMP2 2983/4885 |
| US-20100098659-A1 | COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS | MMP9, MMP14, MMP10 | MMP3 6/4885MMP1 12/4885MMP2 11/4885 |
| US-20100028441-A1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | GJA1, GPR180, AQP4 | MMP3 3789/4885MMP1 1096/4885MMP2 3526/4885 |
| US-20100008997-A1 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS | RGS17, RGS16, CHRM3 | MMP3 2197/4885MMP1 1856/4885MMP2 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.